New TB drug candidate passes first safety check in humans

NCT ID NCT05824091

Completed Knowledge-focused Sponsor: Gates Medical Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called MK-7762 in 119 healthy adults to see if it is safe and how the body processes it. Participants received either the drug or a placebo in single or multiple doses. The goal was to check for side effects and measure drug levels in the blood, not to treat tuberculosis. This is a very early step in developing a possible new TB medicine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MK-7762 (TBD09)
What this could lead to: If successful, this could lead to a new drug for tuberculosis, potentially offering a safer or more effective treatment option.
What could go wrong: This is a very early, first-in-human study focused only on safety in healthy volunteers. It does not test whether the drug actually treats TB, and many early-stage drugs fail to show benefit in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBERCULOSIS

Contacts and locations

Locations

Investigational Site

Lincoln, Nebraska, 68502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.